Moderna prices upsized USD 2.6 billion convertible senior notes offering
MRNA•Upsized convertible notes deal priced
Moderna priced an upsized private offering of USD 2.6 billion of 0.00% Convertible Senior Notes due 2032.
- The deal was increased from USD 2 billion.
- Initial purchasers hold an option for an additional USD 400 million.
- Net proceeds are estimated at about USD 2.56 billion.
- Closing is expected Sept. 1.
- Funds are earmarked for capped call costs of about USD 285 million; the remainder will be used for general corporate purposes, including oncology investment or debt repayment.
